Clinical Trials
10 trialsNCT04689659 2025-05-18
Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma
Beijing Boren Hospital
Phase 2 Completed
NCT00081874 2025-04-27
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03792256 2025-03-21
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Children's Oncology Group
Phase 1 Completed
NCT04840875 2024-11-14
Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma
Beijing Boren Hospital
Phase 1 Completed
NCT04938115 2024-06-14
Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia
Hebei Senlang Biotechnology Inc., Ltd.
Phase NA Completed
NCT00611208 2016-11-29
A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)
Virogen Biotechnology Inc.
Phase 2 Completed
NCT00001941 2012-08-20
Anti-Tac for Treatment of Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00095381 2012-01-19
Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia
BioCryst Pharmaceuticals
Phase 2 Completed
NCT00001249 2008-03-04
Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00001533 2006-07-17
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine
National Institutes of Health Clinical Center (CC)
Phase 1 Completed